Eisai Receives Approval in Russia for its Antiepileptic Treatment Zonegran (Zonisamide) for Use in Children and Adolescents Hatfield, England (ots/PRNewswire) - Zonegran(R) (zonisamide) receives approval in Russia for the treatment of partial epilepsy in children and adolescents. Epilepsy is one of the most common neurological diseases in the world.[2] Around three out of every 1,000 people in Russia live with epilepsy, 82% of whom have partial (focal) epilepsy.[3] Epilepsy diagnosed in childhood has long-term implications for health and well-being and timely diagnosis and appropriate treatment are essential.[4] Although epilepsy is common among children, only two thirds of those with the condition will achieve seizure control and many will require additional AEDs to improve seizure control.[5] "It is good news that we have a new treatment option available for children and adolescents with partial epilepsy in Russia. Epilepsy can affect every aspect of a child's and their family's life; well-tolerated and effective treatments are therefore very welcome," commented Andrey Petrukhin, Professor of the Child Neurology Department at the Russian State Medical University, Russia. This paediatric approval in Russia is based on Study 312 (CATZ) published in Epilepsia in July 2013.[6] The double-blind, randomised, multicentre, placebo-controlled Phase III study showed that significantly … Continue reading →

Hatfield, England (ots/PRNewswire) Zonegran(R) (zonisamide) receives approval in Russia for the treatment of partial epilepsy in children and adolescents. Zonisamide, a novel anti-epileptic drug (AED) with multiple mechanisms of action and a chemical structure unrelated to any other AED, is indicated in Russia and Europe as monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; and as adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents and children aged six years and above.[1] Epilepsy is one of the most common neurological diseases in the world.[2] Around three out of every 1,000 people in Russia live with epilepsy, 82% of whom have partial (focal) epilepsy.[3] Epilepsy diagnosed in childhood has long-term implications for health and well-being and timely diagnosis and appropriate treatment are essential.[4] Although epilepsy is common among children, only two thirds of those with the condition will achieve seizure control and many will require additional AEDs to improve seizure control.[5] It is good news that we have a new treatment option available for children and adolescents with partial epilepsy in Russia. Epilepsy can affect every aspect of a childs and their familys life; … Continue reading →

State senator advocated for the decriminalization of medical cannabis oil for treating intractable epilepsy By James Q. Lynch, The Gazette November 16, 2014 | 4:00 am CORALVILLE State Sen. Joe Bolkcom, D-Iowa City, has been awarded the Epilepsy Foundation of Iowas first Legislator of the Year award for advocating for the decriminalization of medical cannabis oil for the treatment of intractable epilepsy. Bolkcom led the passage of a bill in the Iowa Legislature that created a licensing system allowing patients with intractable epilepsy and their caregivers to pursue treatment with cannabidiol, an oil derived from marijuana that has been shown to reduce seizures. Hes been on the front lines for us for a long time, not just on cannabidiol, but funding and treatment options, said Dale Todd, of Cedar Rapids, the legislative chairman of the Epilepsy Foundation of Iowa. The award was made Saturday at the Iowa Seizure Smart Conference in Coralville, which was presented by the Epilepsy Foundation of Iowa and the Epilepsy Foundation, and sponsored by University of Iowa Health Care. See the original post: Epilepsy foundation awards Iowa City lawmakers efforts … Continue reading →

November 16, 2014 Rayshell Clapper for redOrbit.com Your Universe Online Every day, across the United States, some little kid loses a tooth, which means every night that same little kid has a magical visit from the tooth fairy who replaces it with money. But what happens to those teeth? Sure, they may be stored away as keepsakes, but thats a lot of baby teeth for parents to pack away. Scientifically, there are some serious benefits in studying those teeth. In fact, the Radiation and Public Health Project started a program called the Tooth Fairy Project. This project has participating families send the baby teeth in so that they can study them, specifically looking at elements the teeth have been exposed to since inception. The program looks for Radioactive Strontium-90 (Sr-90) because it is so deadly, and like calcium the body stores it in the bones and teeth indefinitely. Sr-90 will continue to emit cancer-causing radiation, so studying baby teeth will help researchers accurately determine when and where radioactivity was absorbed from the environment. But this is not the only study for which the Tooth Fairy Project has proven to be a benefit. According to the University of California San Diego … Continue reading →